drugset
drugset / Trial / NCT01069328

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

NCT01069328 ↗

Phase 1 Completed 33 enrolled Bayer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.

Timeline

Start
2006-07
Primary completion
2011-09
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 2.5 mg/kg Intravenous
Subject Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Subject Sorafenib Small molecule 200 mg Oral
Subject Sorafenib Small molecule 400 mg Oral
Background Carboplatin Small molecule 6 unknown Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous

Indications

non-small cell lung carcinoma